1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Drugs In Development, 2022, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 3 and 2 respectively.
Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Inclusion Body Myositis (IBM) - Overview
- Inclusion Body Myositis (IBM) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Inclusion Body Myositis (IBM) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
- Inclusion Body Myositis (IBM) - Drug Profiles
- Inclusion Body Myositis (IBM) - Dormant Projects
- Inclusion Body Myositis (IBM) - Discontinued Products
- Inclusion Body Myositis (IBM) - Product Development Milestones
- Featured News & Press Releases
- Nov 05, 2021: Abcuro to present late-breaking abstract at American College of Rheumatology Convergence 2021 of ABC008 inclusion body myositis phase 1 data demonstrating proof of mechanism for selective depletion of highly cytotoxic T cells
- Oct 06, 2021: Abcuro to present trial in progress poster on a phase 1 clinical trial of ABC008 demonstrating targeted depletion of large granular lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress
- Jun 30, 2021: Abcuro and ImaginAb share initial results of study using novel technology for imaging T cell infiltration of skeletal muscle in patients with inclusion body myositis
- Apr 01, 2021: Nobel Pharma announces notice of designation of orphan drug
- Aug 22, 2017: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy
- Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union
- Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
- Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency
- May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
- Jan 12, 2015: Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
- Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
- Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
- Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
- Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress
- Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Inclusion Body Myositis (IBM), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Inclusion Body Myositis (IBM) - Pipeline by AAVogen Inc, 2022
- Inclusion Body Myositis (IBM) - Pipeline by Abata Therapeutics, 2022
- Inclusion Body Myositis (IBM) - Pipeline by Abcuro Inc, 2022
- Inclusion Body Myositis (IBM) - Pipeline by Alzheon Inc, 2022
- Inclusion Body Myositis (IBM) - Pipeline by Cleave Therapeutics Inc, 2022
- Inclusion Body Myositis (IBM) - Pipeline by Leadiant Biosciences Inc, 2022
- Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, 2022
- Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, 2022
- Inclusion Body Myositis (IBM) - Pipeline by PhaseBio Pharmaceuticals Inc, 2022
- Inclusion Body Myositis (IBM) - Pipeline by Vandria SA, 2022
- Inclusion Body Myositis (IBM) - Dormant Projects, 2022
- Inclusion Body Myositis (IBM) - Discontinued Products, 2022
- Number of Products under Development for Inclusion Body Myositis (IBM), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AAVogen Inc
- Abata Therapeutics
- Abcuro Inc
- Alzheon Inc
- Cleave Therapeutics Inc
- Leadiant Biosciences Inc
- Milo Biotechnology LLC
- Nobelpharma Co Ltd
- PhaseBio Pharmaceuticals Inc
- Vandria SA
